D. Boral Capital initiated coverage of Prelude Therapeutics (PRLD) with a Buy rating and $9 price target Prelude is a clinical-stage oncology company advancing a precision medicine approach through a diversified pipeline targeting epigenetic and DNA damage response pathways, the analyst tells investors in a research note. The firm cites the company’s “deep pipeline, emerging clinical validation, and multiple near-term catalysts that could unlock meaningful shareholder value” for the Buy rating. D. Boral believes Prelude has validated its JAK2 franchise through a program-specific agreement with Incyte.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
- Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
- Prelude Therapeutics Prices Public Offering to Extend Runway
- Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
- Prelude Therapeutics presents new preclinical data from PRT13722 study